Author Affiliations: Polyclinique de Dermatologie et Vénéréologie (Drs Parmentier, Antille, and Borradori), Service de Maladies Infectieuses (Drs Garzoni and Kaiser), and Laboratoire Central de Bactériologie (Dr Ninet), Hôpital Universitaire de Genève, Genève, Switzerland.
This article was corrected | View correction
Chronic meningococcemia (CM) is a diagnostic challenge. Skin lesions are frequent but in most cases nonspecific. Polymerase chain reaction (PCR)–based diagnosis has been validated in blood and cerebrospinal fluid for acute Neisseria meningitidis infection, in patients in whom routine microbiologic tests have failed to isolate the bacteria. In 2 patients with CM, we established the diagnosis by a newly developed PCR-based approach performed on skin biopsy specimens.
Two patients presented with fever together with systemic and cutaneous manifestations suggestive of CM. Although findings from blood cultures remained negative, we were able to identify N meningitidis in the skin lesions by a newly developed PCR assay. In 1 patient, an N meningitidis strain of the same serogroup was also isolated from a throat swab specimen. Both patients rapidly improved after appropriate antibiotherapy.
To our knowledge, we report the first cases of CM diagnosed by PCR testing on skin biopsy specimens. It is noteworthy that, although N meningitidis–specific PCR is highly sensitive in blood and cerebrospinal fluid in acute infections, our observations underscore the usefulness of PCR performed on skin lesions for the diagnosis of chronic N meningitidis infections. Whenever possible, this approach should be systematically employed in patients for whom N meningitidis infection cannot be confirmed by routine microbiologic investigations.
Neisseria meningitidis infections are known for their different clinical presentations besides acute meningitis. Among them, subacute or chronic meningococcemias (CMs) are usually difficult to diagnose, owing to either misleading or incomplete presentations or to the difficulty in identifying the bacteria in human samples by using routine microscopic and culture techniques. A new generation of technology based on the real-time amplification of the N meningitidis genome has been proven sensitive and specific to detect the bacteria in human blood and cerebrospinal fluid (CSF) and characterize its serogroup. This has proven highly valuable when false-negative culture findings are induced by previous blind antibiotherapy or a low bacteria load does not allow detection by direct examination or culture.1
Herein, we describe 2 patients presenting with CM. Although findings from all routine microbiologic investigations remained negative, infection with N meningitidis was confirmed by a polymerase chain reaction (PCR) assay performed on skin biopsy specimens. The serogroups were also defined by an amplification method. We discuss the relevance of skin sampling to help diagnose N meningitidis infection and recommend integrating PCR detection to rescue potential false-negative results obtained with the usual microbiologic techniques.
A 23-year-old man was admitted to our clinic for evaluation of fever with body temperature up to 40°C, a 1-week history of gonalgia, a skin rash, and a reduced general condition. The fever had started 4 weeks prior to admission on his return from Morocco. On physical examination, he had arthritis of the right knee. He also had macular erythematous and purpuric lesions disseminated all over his body surface, including 1 sole (Figure 1). Laboratory investigations revealed an inflammatory syndrome. Clinical features and settings raised the possibility of a septicemia related to an N meningitidis or Neisseria gonorrhoeae infection or to Mediterranean spotted fever. Immediately after sampling, empirical antibiotherapy combining ceftriaxone sodium, 2 g, and doxycycline, 100 mg, daily was started. The patient's status dramatically improved, and he was clear of symptoms 48 hours later. Both blood and synovial liquid culture findings remained negative. Repeated serologic tests for Rickettsia conorii were negative too. Using PCR, we searched for N meningitidis on a skin lesion; the test was positive after the patient's discharge from the hospital and thus confirmed our clinical suspicion. Using a PCR-based genogrouping method, we were also able to identify a serogroup B strain. Prophylactic treatment was initiated in all contact subjects.
Representative example of the skin lesions observed in case 1. A discrete purpuric macule is observed on the forearm.
A 17-year-old male was admitted with moderate fever associated with pharyngitis and diarrhea of 10 and 3 days’ duration, respectively. He also developed a transient skin rash, comprised of several erythematous macular and slightly infiltrated lesions, and a purpuric component on his lower limbs and feet (Figure 2). The rest of the physical examination was unremarkable. A mild biologic inflammatory syndrome was found. A septicemia owing to N gonorrhoeae or N meningitidis was first considered, although viral lesions were also possible. The patient was given ceftriaxone sodium, 1 g, intramuscularly, that resulted in a rapid improvement of all physical signs. Direct examinations and cultures performed on blood and skin biopsy specimens remained sterile for the 2 suspected bacteria. Several viral serologic tests showed no active infection (hepatitis A, B, or C viruses; Epstein-Barr virus; human immunodeficiency virus; adenovirus; enterovirus; echovirus; parvovirus B19). A few days after the patient's discharge from the hospital, the presence of DNA sequences of N meningitidis was detected by PCR in the skin biopsy specimen. At the same time, a throat swab culture was positive for N meningitidis serogroup C. The serogroup C was also identified by PCR. These findings confirmed the diagnosis of CM. Contact subjects were given prophylactic antibiotherapy.
Representative example of skin lesions found in case 2, a macular lesion with a central purpuric and necrotic component on the ankle.
The N meningitidis– specific PCR was performed on a skin biopsy specimen according to the following procedure. A fresh skin punch biopsy specimen was processed immediately after sampling. After a disruption step, small pieces of the biopsy specimen were put in 200 μL of a bacterial lysis buffer (Roche Diagnostic Ltd, Basel, Switzerland). A cocktail of enzymes (2 μL of LYT 030, the universal lysis kit used for DNA extraction in bacteria) was added and incubated for 30 minutes at 37°C. The DNA was automatically extracted with the MagNa Pure compact system (Roche Diagnostic Ltd). The samples were directly tested with the nucleic acid isolation kit I and the blood protocol. The elution volume was 100 μL. Three repetitions of 5 μL of extracted DNA were amplified with a real-time PCR TaqMan method using the capsular transport gene (ctra) for N meningitidis.2 The serogroups were identified by the same methods but with the sialic acid gene (siaD) encoding the polysialyltransferase responsible of sialic acid–containing polysaccharides in strains belonging to serogroups B, C, Y, and W135.3 The sequences of each primer and probe are described in the Table. The positive PCR results for N meningitidis genome amplification and the positive PCR result for the serogroup C strain are presented in Figure 3.
TaqMan curves obtained after 45 cycles of real-time polymerase chain reaction (PCR) on DNA material yielded from lesional skin from case 2. Each panel shows 3 replicates of each analysis (green, red, and yellow). Each point represents a value of the fluorescent signal at different times of the amplification run. When the measured fluorescent signal exceeds a calculated background threshold identifying amplification of the targeted sequence, a cycle threshold (Ct) value is defined. A, Sample of skin and PCR for Neisseria meningitidis. Ct value = 29. B, Sample of skin and PCR for N meningitidis serogroup C, Ct = 29. C, Negative control (no template control), Ct value = 45. D, Positive control (100 pg of N meningitidis DNA), Ct = 21.
Chronic meningococcemia is defined as a sepsis caused by N meningitidis lasting more than 1 week and presenting without meningeal signs. Most reports, including the first description,4 underscore the potential prolonged course of the disease with a spontaneous relapsing evolution. Fever is almost constant, and arthralgias are frequent.5 The cutaneous manifestations, which are observed in up to 50% of the cases, are variable, including purpuric papules and nodules, and urticarial eruptions.6,7 Therefore, the clinical presentations of our 2 patients were suggestive of CM. Nevertheless, in the patient presenting with a 10-day course, the disease could also be defined as occult meningococcemia.
Two points should be emphasized. First, without appropriate treatment, the disease is likely to worsen, affect vital functions, and become life threatening.8 Carditis and meningitis with fatal outcomes have been described.8 Second, early diagnosis is often a challenge: false-negative findings from blood cultures are not unusual, and repeated samplings are frequently required. Hence, identification of the responsible bacteria for guiding appropriate antibiotherapy is frequently delayed or made only after the patient's discharge from the hospital.9 Therefore, a new, specific, and sensitive microbiologic test allowing for rapid confirmation of the diagnosis is highly desirable and needed.
How can the dermatologist contribute in tackling these issues? Bacterial cultures on skin biopsy samples have been reported to be valuable diagnostic tools in acute N meningitidis infections. Rapid diagnosis by Gram staining of needle aspirates or biopsy specimens of skin lesions yielded a sensitivity of 72% in meningococcal sepsis.10 In another retrospective study,11 a sensitivity of 80% was obtained for Gram staining smears using material scraped from petechial lesions. Moreover, the test was positive in 17 of 19 patients (89%) with negative findings from blood cultures, allowing reassessment of diagnosis and appropriate treatment. In prospectively studied patients with skin lesions and presumed acute meningococcal diseases, Arend et al12 obtained a sensitivity of 56% through a combination of Gram stain and culture of skin biopsy specimens. Four of 25 patients with positive findings from skin biopsy specimens had negative blood cultures.
Nevertheless, these studies focused on acute forms of N meningitidis infections, whereas in CM, the identification and isolation of the bacteria are usually more challenging. Thus far, sensitivity of skin cultures and Gram stain has not been evaluated in CM. One report13 of CM has been published in which the bacteria was successfully cultured on skin biopsy specimens only. We report 2 additional observations of CM with negative findings from blood cultures. In both cases, the diagnosis was assessed by the use of a newly developed N meningitidis–specific PCR on skin specimens. The PCR was unfortunately not tested in parallel in blood samples. Interestingly, the 2 patients described herein were infected by 2 different strains (serogroup B and serogroup C) that are known to be invasive. In the past decade, the PCR-based diagnosis has proven a valuable tool in the assessment of patientS with invasive meningococcal disease.14 Previously, in meningococcal infections, approximately 90% and 50% of untreated patients had positive CSF or blood culture findings, respectively, a rate decreasing to 5% or less after early antibiotic treatment.15 Nonculture methods like Gram staining or direct immunodetection of capsular polysaccharide are frequently not sensitive enough to detect the presence of the bacteria.16 A PCR-based diagnosis, performed either on blood or CSF samples, has been validated as a robust tool to assess the diagnosis in these difficult situations.17,18 In addition, Fox1 has already underscored the potential gain in sensitivity in developing PCR methods applied to DNA isolated from additional clinical specimens like skin scrapings or biopsy specimens. Yet, to our knowledge, there have been no reports of successful PCR testing for N meningitidis on skin samples.
We used a fluorescence-based PCR method on DNA extracted from lesional skin. The approximate time needed to obtain a definite result is less than 4 hours, with an additional 3 hours needed to determine the serogroup. In 1 of our cases, the concomitant isolation of the same serogroup N meningitidis on a throat biopsy sample provided additional evidence for the imputability of the identified bacteria. The failure to detect N meningitidis in blood by culture is probably related to the intermittent nature of the bacteriemia, whereas in skin biopsy specimens, both dead and alive bacteria are available for PCR detection. Based on our encouraging but preliminary results in 2 patients, it is important that future prospective studies validate the value of N meningitidis–specific PCR and compare its sensitivity with both PCR in blood samples and Gram staining of needle aspirates or skin scrapings. Nevertheless, PCR on skin biopsy specimens seems to constitute a valuable tool to validate the diagnosis of CM, at least in forms in which standard diagnostic procedures are known to have a substantial failure rate. Moreover, it is likely that this approach could be employed successfully in acute N meningitidis infections. The technique requires less than 3 hours of laboratory work, assuming that the DNA extraction yield is the limiting step. The cost of the reagent is reasonable and comparable with a standard hemoculture. Therefore, assuming that a skin biopsy is easily performed by a trained physician and that the sample is immediately transferred to the laboratory, we consider it a valuable tool for outpatients when meningococcemia is suspected. To optimally evaluate the potential benefit of using skin biopsy samples as the substrate for PCR, further prospective studies should compare its sensitivity with results obtained in blood and/or CSF.
Correspondence: Laurent Parmentier, MD, PhD, Polyclinique de Dermatologie et Vénéréologie, Hôpital Universitaire de Genève, Rue Micheli-du-Crest 24, 1211 Genève 14, Switzerland (email@example.com)
Accepted for Publication: October 21, 2007.
Author Contributions: Drs Parmentier and Garzoni had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Parmentier, Garzoni, Kaiser, and Borradori. Acquisition of data: Garzoni, Antille, Ninet, and Borradori. Analysis and interpretation of data: Parmentier, Garzoni, Antille, Kaiser, and Ninet. Drafting of the manuscript: Parmentier, Garzoni, Antille, and Ninet. Critical revision of the manuscript for important intellectual content: Parmentier, Kaiser, and Borradori. Administrative, technical, and material support: Antille and Ninet. Study supervision: Parmentier, Garzoni, and Borradori.
Financial Disclosure: None reported.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 5
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.